EMAIL THIS PAGE TO A FRIEND

Anticancer research

High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.


PMID 26637889

Abstract

A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. The present study aimed to further explore this finding in malignant pleural mesothelioma (MPM). Seventy-one patients with MPM receiving first-line chemotherapy with cisplatin-vinorelbine (CiV group, n=54) or carboplatin-pemetrexed (CaP group, n=17) were included. Formalin-fixed paraffin-embedded tumor specimens were analyzed by immunohistochemistry (IHC) for RRM1 expression using an H-score. In 66 patients eligible for IHC, the H-score was ≥upper quartile in 21 (RRM1-positive) and

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

EHU017091 MISSION® esiRNA, esiRNA targeting human RRM1 (esiRNA1)